Rankings / Hormones & Endocrine
Finasteride (oral / topical)
Hormones & Endocrine · 5-alpha reductase inhibitor (type II)
Also known as: Propecia ·Proscar
Tier A-
Bottom line
Read Off Label grades Finasteride (oral / topical) as A- (7.6/10) based on strong evidence, strong benefit magnitude, and a low-med-risk safety profile.
Topical formulations aim to reduce systemic exposure and sexual side effects; emerging RCT data (Piraccini 2022) shows similar efficacy with lower systemic DHT reduction.
Studied, labeled, or reported-use context: Oral: 1 mg/day (AGA) or 5 mg/day (BPH); topical 0. — Rx; not individualized guidance.
If you were testing this on yourself
Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.
Can you undo it?
Potentially permanent
Most users who stop return to baseline, but persistent sexual and neurological symptoms after discontinuation are reported often enough to be recognised in the literature and in regulatory labelling. A minority do not return to baseline. That possibility, not the frequency, is the decision-relevant fact.
Can you tell if it worked?
Readable — 6–12 months to judge a hair response
Standardised photographs at fixed lighting and angle; hair-density counts.
What would fool you Hair loss progresses over the same timescale, so "no change" may be a success. Photographic conditions have to be genuinely fixed or the comparison is worthless. It also suppresses PSA by roughly half, which matters for future cancer screening and needs to be on your record.
What the evidence says
Topical formulations aim to reduce systemic exposure and sexual side effects; emerging RCT data (Piraccini 2022) shows similar efficacy with lower systemic DHT reduction. Persistent post-finasteride symptoms are reported; incidence and causality remain debated. Pregnancy exposure can affect male fetal development and is contraindicated in product labeling.
Mechanism
Selective inhibitor of 5-alpha reductase type II; reduces DHT ~70% systemically (oral) or locally (topical); preserves/regrows hair in androgenetic alopecia; also FDA-approved for BPH
Studied, labeled, or reported dose & route
Oral: 1 mg/day (AGA) or 5 mg/day (BPH); topical 0.25-0.5% solution (compounded)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Finasteride (oral / topical)'s effects?
- Read Off Label rates the evidence for Finasteride (oral / topical) as Strong and the benefit magnitude as strong, producing an overall grade of A- (7.6/10). Topical formulations aim to reduce systemic exposure and sexual side effects; emerging RCT data (Piraccini 2022) shows similar efficacy with lower systemic DHT reduction.
- What safety findings are reported for Finasteride (oral / topical)?
- Finasteride (oral / topical) has a low-med risk profile in the database. Low-Med (sexual side effects — ED, libido, reduced ejaculate volume; mood/cognitive effects debated — 'post-finasteride syndrome' controversial but reported; small decreased PSA affecting screening interpretation; gynecomastia) Legal status: Rx.
- What doses or routes are reported for Finasteride (oral / topical)?
- Oral: 1 mg/day (AGA) or 5 mg/day (BPH); topical 0.25-0.5% solution (compounded) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Finasteride (oral / topical) work?
- Selective inhibitor of 5-alpha reductase type II; reduces DHT ~70% systemically (oral) or locally (topical); preserves/regrows hair in androgenetic alopecia; also FDA-approved for BPH
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.